The association of CHEK2 mutation with metastasis appears paradigmatic but gender dependent: A pan-cancer analysis across >10 different cancer types demonstrated 1.8-fold enrichment for CHEK2 (P = 0.045), but not ATM, mutations in metastatic relative to primary tumors only in women, not in men (Fig. 6E). Here, CHEK2 is linked to cancer.